News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Argos Therapeutics, Inc. Identifies Immune Response Marker Connected to Prolonged Overall Survival in mRCC Patients Treated With AGS-003



10/11/2012 9:16:24 AM

DURHAM, N.C., Oct. 11, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that it has identified a unique immune response signature that significantly correlates with clinical outcomes associated with its Arcelis™ immunotherapy product candidate, AGS-003 being developed for the treatment of metastatic renal cell carcinoma (mRCC). Data presented at the Markers in Cancer Meeting, October 11, Hollywood, Fla., demonstrates that a specific tumor-reactive cytotoxic T cell (CTL) subset (CD28+/CCR7+/CD45RA- phenotype) displaying a broad Markers of Immune Function (MIFs) profile correlates with progression-free survival (PFS) and overall survival (OS) in patients treated with AGS-003.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES